NCT04868253View on ClinicalTrials.gov

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Smoking CessationTobacco Use Disorder
Interventions
DRUG

EMB-01

EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).

Trial Locations (1)

27617

RECRUITING

Rose Research Center, Raleigh

Sponsors
All Listed Sponsors
collaborator

Foundation for a Smoke Free World INC

OTHER

collaborator

Embera NeuroTherapeutics, Inc.

INDUSTRY

lead

Rose Research Center, LLC

INDUSTRY